MAPT and Alzheimer disease: Thus, in addition to site-specific hyperphosphorylation, in vivo treatment with AD P-tau induces site-specific formation of AD-like SDS- and β-mercaptoethanol-resistant and site-specifically hyperphosphorylated HMW-tau.